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Abstract 
Type 2 diabetes has reached epidemic proportions worldwide. The resulting increase in chronic 
and costly diabetes related complications has potentially catastrophic implications for healthcare 
systems, and economics and societies as a whole. One of the key pathological factors leading to 
type 2 diabetes is insulin resistance (IR), which is the reduced or impaired ability of the body to 
make use of available insulin to maintain safe glucose concentrations in the bloodstream. 
It is essential to understand the physiology of glucose and insulin when investigating the 
underlying factors contributing to chronic diseases such as diabetes and cardiovascular disease. 
For many years, clinicians and researchers have been working to develop and use model-based 
methods to increase understanding and aid therapeutic decision support. However, the majority 
of practicable tests cannot yield more than basic metrics that allow only a threshold-based 
assessment of the underlying disorder. 
This thesis gives an overview on several dynamic model-based methodologies with different 
clinical applications in assessing glycaemia via measuring effects of treatment or medication on 
insulin sensitivity. Other tests are clinically focused, designed to screen populations and diagnose 
or detect the risk of developing diabetes. Thus, it is very important to observe sensitivity metrics 
in various clinical and research settings. 
Interstitial insulin kinetics and their influence on model-based insulin sensitivity observation was 
analysed using data from the clinical pilot study of the dynamic insulin sensitivity and secretion 
(DISST) test and the glucose-insulin PK-PD models. From these inputs, a model of interstitial 
insulin dose-response that best links insulin action in plasma to response in blood glucose levels 
was developed. The critical parameters influencing interstitial insulin pharmacokinetics (PKs) 
are saturation in insulin receptor binding (aG) and the plasma- interstiti um diffusion rate (ni). 
Population values for these parameters are found to be [aG, nj][0.05,0.055]. 
Critically ill patients are regularly fed via constant enteral (EN) nutrition infusions. The impact 
Of incretin effects on endogenous insulin secretion in this cohort remains unclear. It is 
XII
hypothesised that the identified S1 would decrease during interruptions of EN and would increase 
when EN is resumed, where, for short periods around transition, the true patient Sj would be 
assumed constant. The model-based analysis was able to elucidate incretin effects by tracking the 
identified model-based insulin sensitivity (Si) in a cohort of critically ill patients. Thus, changes 
in model-based Sj given the fixed assumed endogenous secretion by the model would support the 
presence of an EN-related incretin effect in the population of non-diabetic, critically ill patients 
studied. 
The PD feedback-control model of Uen was designed to investigate endogenous insulin secretion 
amongst subjects with different metabolic states and levels of insulin resistance. The underlying 
effects that influence insulin secretion i.e. incretin effects were also defined by tracking the 
control model gain/response and the identified insulin sensitivity (S i) using intravenous (IV) 
bolus and oral glucose responses of insulin sensitivity tests. This new PD control model allowed 
the characterisation of both static (basal) and dynamic insulin responses, which defined the 
pancreatic fl-cell glucose sensitivity parameters. However, incretin effects were unobserved 
during oral glucose responses as the PD control gains failed to simulate the true endogenous 
insulin secretion due to potentially inaccurate glucose appearance rates and low data resolution 
of glucose concentrations. 
The net effect of haemodialysis (HD) treatment on glycaemic regulation and insulin sensitivity in 
a critically ill cohort was investigated. It was hypothesized that the observed S would decrease 
during HD due to enhanced insulin clearance compared to the model, and would be recaptured 
again when HD is stopped. The changes in model-based S metric at HD transitions in a cohort of 
critically ill patients were evaluated. Significant changes of -29% in model-based S was 
observed during HD therapy. However, there were insignificant changes when HD treatment was 
ended. Thus, the changes in model-based S1 would thus offer a unique observation on insulin 
kinetics and action in this population of critically ill patients with ARF that would better inform 
metabolic care.
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Chapter 1. Introduction 
The number of people with diabetes has significantly increased in recent years to approximately 
350 million people worldwide (Chen et al. 2011). Chronic hyperglycaemia is the main• 
characteristic of diabetes and is directly associated with morbidity and mortality (Capes et al. 
2000; Krinsley 2003; Krinsley 2004; Van den Berghe et al. 2001). In 2004, an estimated 3.4 
million people died due to hyperglycaemia (ADA 2006a). Thus, it is suggested that diabetes has 
reached epidemic proportions, with catastrophic implications on quality of life, healthcare costs 
and population as a whole (Bonow and Gheorghiade 2004; Chiu et al. 2001; King 1999). 
The general symptoms of diabetes can be alleviated with glycaemia control protocols in 
intensive care unit (ICU), which are reported to reduce the risk of other metabolic complications 
i.e. cardiovascular, sepsis, acute renal failure, and etc. (Chase et al. 2008; Evans et al. 2011; 
Krinsley 2004; Van den Berghe et al. 2001). Also, understanding the underlying metabolic 
disorders that contribute to the pathogenesis of diabetes can potentially prevent the risk of 
developing this disease at the very early stage or provide the best approach to treat diabetes 
before it becomes chronic. This chapter discusses the overall prevalence, its development and 
underlying causes of diabetes. Review on its current clinical diagnosis assessment methods and 
glycaemic control protocols for critically ill patients are also presented. 
1.1 Pathogenesis Type II Diabetes Mellitus (T2DM) 
The pathogenesis of T2DM is a more gradual process than type I diabetes. It generally starts 
with the pre-diabetes stages of impaired glucose tolerance (IGT) and impaired fasting glucose 
(IFG), before a clinical classification of diabetes can be made. The progression of this disease is 
often undiagnosed and untreated for many years, until first health complications start to appear. 
The physical symptoms that usually occurred in T2DM are listed as follows: 
• Dehydration and frequent urination. As blood glucose concentration builds up in the 
bloodstream, fluid is absorbed from the tissues which cause dehydration. Thus, it 
increased the fluid consumption and urinates more frequently than normal.
Increased appetite. Without enough insulin to bind with cells in peripheral tissues and 
muscles causes' energy depletion that triggers intense appetite. 
Weight loss. The body uses alternative fuels stored in muscle and fat as source of energy 
due to decreased glucose metabolism in the bloodstream. 
Fatigue. The body becomes tired and exhausted as the cells are deprived of glucose. 
. Blurred vision. This symptom only occurs when hyperglycaemia causes excessive fluid 
appearance in the eyes lenses. 
Low immunity system. T2DM affects the body's ability to heal and resist infections. 
Later, it may cause sepsis if it is untreated. 
Typically, T2DM is not recognised early enough to intervene before permanent damage has 
begun to occur, and is thus often diagnosed only when treating its symptoms or complications at 
later levels (Gastaldelli et al. 2004; Kleinfield 2006). This late diagnosis is due to the nature of 
the disease development, where noticeable symptoms do not arise until significant irreversible 
damage has occurred. With accurate early diagnosis pre-diabetic states could potentially 
identified up to 3-5 years earlier (Andersson et al. 2009; Clark et al. 2000; Pannala et al. 2009) 
which can significantly reduce the onset of further damage and complications. 
T2DM is increasingly diagnosed among children, adolescents and younger adults (Hossain et al. 
2007). The causes of this epidemic disease are embedded in a very complex group of genetic 
besides the integrated between quality of life and environmental influences. Given that both 
insulin secretion and its kinetic are under genetic control, failure of fl-cell function and/or JR 
could theoretically be the primary factors in T213M (DeFronzo and Ferrannini 1991; Kahn 2003; 
Poulton et al. 2002; Staiger et al. 2009; Stumvoll et al. 2005). This common aspect presumably 
reflects the development of JR at the peripheral and receptor level, particularly in the liver, 
skeletal muscle and heart (Andrews and Walker 1999; Reaven 1988; Shulman 2000). 
The chronological treatment of T2DM consists first of lifestyle changes to increase insulin 
sensitivity. Increases in exercise with healthier diet and weight loss are proven to increase insulin 
sensitivity and thus reduce the prevalence or impact of T2DM (Duncan et al. 2003; McAuley et 
al. 2002; Nishida et al. 2004; Tuomilehto et al. 2001). This is may be combined with medication,
such as thiazo! idinedionesn (Rosiglitazone), biguanides (Metform in) or sulfonylureas 
(Glyburdie) to enhance insulin sensitivity or stimulate the pancreas secretion (Kahn et al. 2006). 
Lastly, insulin replacement therapy (i.e. exogenous insulin input via insulin pump) as in type I 
diabetes, is required to maintain glucose homeostasis (Hermansen et al. 2002; Pickup and Keen 
2002; Schaumberg et al. 2005; Steil et al. 2006) 
1.2 Development of model-based S1 test 
The model-based insulin sensitivity methods have shown significant ability to diagnose and 
characterise pre-diabetic state (Beard et al. 1986; Bergman et al. 1987; Boston et al. 2003; Chase 
et al. 2008; Lotz 2007; Mari et al. 2001a; McAuley et al. 2011; Pacini and Bergman 1986; 
Wallace and Matthews 2002). Model-based approaches measure the physiological effects that 
explain the causes to progression of diabetes. Model-based S1 tests typically use empirical 
methods, mostly regression models that are designed to correlate well with certain gold standard 
test metrics i.e. euglycaemic/hyperglycaemic clamp (EIC) (Beard et al. 1986; Bergman et al. 
1987; DeFronzo etal. 1979; Mari et al. 2001a; Pacini and Bergman 1986). 
If fasting metrics are used insulin sensitivity is only quantified during a fasting state which may 
be different to postprandial sensitivity. It is also assumed that the insulin secretion from fl-cells 
can be measured by sampling C-peptide concentrations (Pacini and Mari 2003). The elevated 
insulin concentrations can cause endogenous glucose production inhibition (EGP). The level of 
inhibition can be measured with the additional use of glucose tracers (Caumo and Cobelli 1993). 
Thus, Sj metrics can be different to the real-observed during the dynamic or hyperglycaemic state 
used in other applications (Scheen et al. 1994) as the total S1 is defined as the total amount of 
insulin sensitivity at peripheral cells and liver. 
It is important to model all the kinetic behaviour of insulin and glucose including: insulin 
clearance, endogenous glucose production, endogenous insulin secretion and to segregate the 
dynamics (i.e. incretin effects) to fully describe the important aspects of the true metabolic 
system. Figure 1.1 shows an overview of the physiological effects that can be measured by S 
tests. However, these effects can only be captured by the model depending on the design and 
application of the tests.
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Figure 1.1 Overview of the physiological effects measured by insulin sensitivity tests. Depending on the 
design of the test, it can measure either one, a combined effect if two, or all three of these effects. The 
dashed lines indicate a mediated or enhanced effect. 
The main effects contributing to insulin dependent glucose uptake (in Figure 1.1) which reflect 
the insulin sensitivity are the sensitivity of tissue cells to bind insulin (peripheral sensitivity), the 
effect of insulin on the liver to secrete glucose production (hepatic sensitivity), and the ability of 
the pancreas to produce insulin with increase in glucose concentration (8-cell function). These 
effects are time varying and are different in fasting or perturbed states (Scheen et al. 1994). 
Depending on the structural design of the chosen method to assess S i and its assumptions, one or 
more of these effects can be combined in the assessment. Thus, different clinical and 
physiological interpretations can be delivered depending on varying results obtained from the 
chosen approach. 
1.3 Model-based glycaemic control protocol 
It is reported that model-based glycaemic control (GC) protocols ensure a reduction in 
hypoglycaemia in the ICU (Chase et al. 2007; Chase et al. 2008; Evans et al. 2011; Hovorka et 
al. 2007; Le Compte et al. 2009). The motivation of these protocols is to reduce clinical burden 
in ICU and also lessen the chronic outcomes due to organ failure, which increased morbidity and 
thus mortality. Model-based control relies on a physiological model that captures the glucose-
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insulin system dynamics that accurately predict blood glucose, given specific insulin and glucose 
inputs. A control algorithm can use these predictions to select optimal insulin and nutrition 
interventions for forthcoming periods. 
The potential of models for managing glycaemic levels in critically ill patient is thus becoming 
realised. However, few models have been clinically validated. For most models, the primary 
form of validation has been simple fitting of the model to match clinical data (Carson and 
Cobelli 2001). Occasionally, more rigorous prediction validation, which tests the models ability 
to predict the outcome of a known intervention on retrospective clinical data (or in a clinical 
trial) is used. However, only a few clinically validated models can predict within clinically 
acceptable ranges (Chassin et al. 2004; Lotz et al. 2008; Pielmeier et al. 2010; Plank et al. 2006; 
Wong et al. 2006). 
Despite its clinical uses, glycaemic control (GC) in ICU also introduced secondary benefits. 
Studies by Weekers et al. (2003) and Langouche et al. (2005) indicate that glycaemic control 
reduces glucotoxicity due to high blood glucose, which in turn reduces oxidative stress and 
superoxides, which are stress hormone responses that cause damage to the endothelium and 
vascular walls. 
Simple model-based GC protocols have been successfully developed and piloted (Chase et al. 
2008; Chee et al. 2002; Evans etal. 2011; Fisk etal. 2012; Plank etal. 2006; Shaw etal. 2006). 
These model-based methods are able to identify evolving patient-specific parameters and tailor 
therapy appropriately. The principal of model-based control uses a physiological model that 
relies on a single, time-varying parameter, in this case S1, to capture the patient-specific 
glycaemic response to insulin. As an identified parameter, S 1 is prone to capturing other 
dynamics and metabolic effects which can be used to quantify metabolic dysfunctions and 
variability in critically ill patients. Although maintaining safe, effective model-based glycaemic 
control in critically ill patients has poven difficult, due to considerable inter- and intra- patient 
variability, it may offer the most practical, robust, adaptive and patient-specific solution to 
manage this issue. Success is thus a function of the model's ability to accurately capture the 
dynamics of insulin kinetic over time in the highly variable critically ill patient. 
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1.4 Preface 
The objective of this thesis is to understand and validate various pharmacokinetic and 
pharmacodynamic (PK-PD) models in wider research and clinical settings and present analyses 
of several important insulin kinetic and metabolic dysfunctions which affect the model-based 
insulin sensitivity. 
This thesis focuses on the kinetic parameters of the (PK-PD) models that affect the insulin 
secretion, insulin transport kinetics, incretins, and insulin clearance. Additionally, the impact of 
haemodialysis treatment in critically ill patients and the renal insulin clearance and insulin 
secretion were also presented. A brief overview of the thesis includes: 
Chapter 2 presents the physiology of plasma insulin, glucose, C-peptidemnd incretins. 
Chapter 3 reviews current model-based S1 assessments used in research and clinical settings and 
its applications. 
Chapter 4 investigates the modelling of interstitial insulin actions, using different clinical-
validated PK and PD models with DISST data. 
Chapter 5 quantify and analyses the incretin effects of critically ill patients that underwent the 
SPRINT protocol. 
Chapter 6 develops a control model for pancreatic insulin secretion as a function of glucose 
excursions. 
Chapter 7 assesses the impact of haemodialysis (HD) therapy on insulin kinetics and action in 
critically ill patients with acute renal failure. 
Chapter 8 and 9 summaries the key aspects of the thesis and present possible future applications 
for this research.
Chapter 2. Physiology of Plasma Insulin, Glucose, C-peptide and 
Incretins 
This chapter describes the physiology and biochemical characteristics of insulin, glucose, C-
peptide and incretin. These effects are captured in dynamic models that seek to segregate the 
dynamic effects of insulin' sensitivity, insulin secretion and other metabolic effects. Hence, it 
provides foundation of the necessary basic knowledge needed to create effective, realistic 
models. 
2.1 Glucose 
Glucose (C6H 1206) is a monosaccharide used as the main source of energy in the body. It is 
oxidised in the cells to generate adenosine triphosphate (ATP) molecules which in turn provides 
energy to the cell (Guyton and Hall 2000). Glucose is transported around the body passively in 
the bloodstream. It also can be diffusively without insulin taken up by cells in the brain and the 
central nervous system, as they are highly permeable to glucose. However, muscle, adipose 
tissue cells and intestinal cells contribute to a majority of the total uptake. If available in 
abundance, glucose is stored by the liver and peripheral cells as glycogen for future use (Guyton 
and Hall 2000; Zierler 1999). Most of the body's cells require the hormone insulin to mediate 
glucose uptake (Despopoulos and Silbernagl 2003; Guyton and Hall 2000). Thus, insulin acts as 
a biochemical signal that unlocks cellular pathways of cellular glucose uptake, rather than as an 
integral part of that uptake. Hence, this uptake is referred to as insulin-mediated. 
Glycogenesis is the process of storing excess circulating glucose as glycogen in the liver. If 
glycogen stores are saturated, glucose is converted into fat and stored in the liver and in fat cells 
in the adipose tissue. These processes can be reversed when the energy demand is high. Glucose 
is rapidly released from glycogen via the glycogenolysis process if glycogen stores are used, 
once fat is used via the gluconeogenesis process with amino acids to form glucose (Guyton and 
Hall 2000; Zierler 1999).
Both glycogenolysis and gluconeogenesis are commonly grouped under and described as 
endogenous glucose production (EGP) (Zierler 1999). EGP is tightly regulated in the healthy 
body to maintain basal (minimum) blood glucose concentration. EGP represents net glucose 
produce by the body, primarily by the liver, and released into the blood (Cherrington 1999). EGP 
is suppressed when blood glucose concentration is considerably high due to external glucose 
appearance through meals or to a lesser extent via intravenous bolus (Caumo and Cobelli 1993; 
Jefferson et al. 2001; Pretty 2012). However, low glucose concentrations inverse the process by 
stimulating glucagon secretion via pancreatic a-cells, which activates glycogenolysis and thus 
rapidly increases glucose concentrations to prevent hypoglycaemia. 
The rate of endogenous glucose production is a function of both stimulus and availability of 
substrates. In reality, EGP is modulated by the interaction of many hormones in response to 
metabolic dysfunctions that cause insulin sensitivity irregularities (Gelfand et al. 1984; Mizock 
2001). As tissue cells fail to respond adequately to insulin, blood glucose concentrations rise. 
Normally, the liver helps regulate glucose concentrations by reducing glucose production in the 
presence of insulin. However, this may not occur in T2DM due to insulin resistance that reduced 
glycogen synthesis and storage and a failure to suppress glucose production. In critical illness, 
this lack of suppression of EGP is enhanced (Capes et al. 2000; McCowen et al. 2001; Thorell et 
al. 2004). 
The body naturally regulates blood glucose levels as a part of metabolic homeostasis. It is 
suggested that healthy fasting blood glucose concentration ranges between 4.4-5.1 mmol.U' (80-
92 mg.dL'). Prolonged malnutrition or exposure to insulin can result in mild hypoglycaemia 
(low blood glucose <4.0 mmol.L' or 72 rng.dU'). Severe hypoglycaemia (<2.2 mmol.U 1 or 40 
mg.dU') can limit the availability of energy to the brain and nervous system that can cause un-
consciousness or death. Alternatively, hyperglycaemia is also dangerous and occurs when blood 
glucose is elevated above safe levels (>11.1 mmol.L' or 200 mg.dL) with mild hyperglycaemia 
is defined as BG>7.0 mmol.U' (125 mg.dL 1 ). A subject with a fasting blood glucose range 
between 5.6 and 7 mmol.U' can be diagnosed with impaired glucose tolerance (IGT), while >7 
mmol.L 1 (125 mg.dU 1 ) can diagnose type 2 diabetes. Prolonged hyperglycaemia is highly toxic 
to a wide range of tissues and can result in diabetic retinopathy leading to partial blindness; and 
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decay of peripheral capillaries which may finally require body parts be amputated. Importantly, a 
continuous glucose homeostasis to normal levels is essential for positive on-going health 
benefits, and is equally true for hyperglycaemic critically ill patients. 
2.2 Plasma Insulin 
Insulin is a hormone secreted by the pancreas within the fl-cells of the islets of Langerhans. 
Within the islets of Langerhans, fl-cells constitute 65-80% of all the cells. Insulin has a leading 
role in maintaining glucose homeostasis. It enables glucose uptake by muscle and adipose tissue 
cells, regulates storage and release of glucose in the liver and promotes fat synthesis and storage 
(Guyton and Hall 2000; Jefferson et al. 2001). The pancreas secretes plasma insulin into the 
portal vein, where it first passes through the liver and subsequently enters systemic circulation. 
Glucose uptake is activated once plasma insulin is distributed to interstitial fluid, where it binds 
to cell-membrane receptors (Jefferson et al. 2001) as shown in Figure 2.1 
Insulin secretion by the pancreas is bi-phasic in healthy subjects (Guyton and Hall 2000; 
Jefferson et al. 2001; Prager et al. 1986; Sherwin et al. 1974). The first phase is a release of 
stored insulin in response to significant changes in glucose concentration. The magnitude of the 
first phase insulin secretion is typically to the rate of changes in glucose and the glucose gradient 
between the periphery and the portal vein (Cherrington 1999). 
The second phase is a prolonged, slow release of newly formed insulin dependent on glucose 
concentration. When the first phase insulin secretion is diminished, blood glucose concentrations 
will increase significantly right after oral ingestion. The pancreas compensates for this rise by 
increasing the second phase insulin secretion, which eventually brings blood glucose 
concentrations back to normal. However, these high levels of glucose and insulin in the 
bloodstream may damage the fl-cells and further impair their ability to function. As a result, 
hyperglycaemia and T2DM occur in conjunction with hyperinsulinemia as a result of increased 
insulin resistance.
This response to glucose can be broadly modeled using a proportional-derivative (PD) feedback 
controller. This approach has been used to attempt closed loop control of diabetes and for tight 
glycaemic control (TGC) for critically ill patients (Chase et al. 2006; Chee et al. 2003; Steil et al. 
2006). Its popularity in representing insulin secretion is the basis for its use in glycaemic 
controllers.
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Figure 2.1 Schematic of insulin binding to receptors on tissue cells to activate glucose uptake. (Figure 
taken from medicinexplained.blogspot.co.nz). 
Circulating insulin is mainly cleared through by the liver, accounting for up to 60% of total 
insulin clearance (Duckworth et al. 1988; Ferrannini and Cobelli 1987; Sherwin et al. 1974). 
Approximately 30-60% of endogenous insulin is extracted by the liver in the first pass after it is 
released into the portal vein (Duckworth et al. 1988; Ferrannini and Cobelli 1987; Prager et al. 
1986; Sherwin et al. 1974; Toffolo et al. 2006). This mechanism allows a fast response and 
control insulin circulation and kinetics. Insulin is also cleared by the kidney (Duckworth et al. 
1998; Mak 1995; Rabkin et al. 1984) and through cellular degradation after binding to allow 
glucose uptake in the periphery (Guyton and Hall 2000; Jefferson et al. 2001). Insulin has two 
different half-lifes at 4-6 minutes and 20-30 minutes (Duckworth et al. 1998; Turnheim and 
Waldhausl 1988).
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